Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00334776 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Metastatic Melanoma
A Phase 2 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00334776 is a Phase 2 study that has completed, run by University of Southern California. The registered enrollment target is 6 participants.
The verdict
NCT00334776, a Phase 2 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill melanoma cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with metastatic melanoma.
Interventions
- BIOLOGICAL MART-1 antigen
- BIOLOGICAL gp100:209-217(210M) peptide vaccine
- BIOLOGICAL tyrosinase peptide
- BIOLOGICAL therapeutic autologous dendritic cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2003-10 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00334776
The ClinicalTrials.gov registry entry for NCT00334776 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which MART-1 antigen is the first listed.
NCT00334776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00334776 about?
NCT00334776 is a clinical study titled "Vaccine Therapy in Treating Patients With Metastatic Melanoma". RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill melanoma cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with metastatic melanoma.
What is the current status of trial NCT00334776?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2003-10. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00334776?
The interventions under investigation include: MART-1 antigen (BIOLOGICAL), gp100:209-217(210M) peptide vaccine (BIOLOGICAL), tyrosinase peptide (BIOLOGICAL), therapeutic autologous dendritic cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00334776?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.